13F filerCIK 1061768 ↗

Baupost Group

You are looking at Q4 2018. See the latest, Q3 2026 →

Reported value

$11.52B

−12% on the quarter before

Positions

37

6 new, 7 sold out

Top 10

72.7%

of the value

Est. gain

−$1.89B

on stocks held all quarter

Est. return

−16.5%

on those stocks since Q3 2018

Filed

Feb 13, 2019

On SEC EDGAR ↗

Positions as of Dec 31, 2018, from Baupost Group's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

  • New
  • Added
  • Cut
  • Same
  • Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2018. Striped tiles are options.

Twenty First Centy Fox Inc21%
Cheniere Energy Inc7.3%
Twenty First Centy Fox Inc7.1%
Viasat Inc7.0%
Qorvo5.6%
Allergan Plc5.5%
Liberty Global Plc5.3%
Pioneer Nat Res Co5.1%
Ebay Inc5.1%
13 others3.9%
Pg&E Corp3.2%
Tesla3.2%
Synchrony Finl3.0%
Antero Res Corp2.3%
Theravance Biopharma Inc2.1%
Colony Cap Inc New2.0%
Atara Biotherapeutics Inc1.9%
Mckesson Corp1.6%
Univar Inc1.5%
Amerisourcebergen Corp1.3%
Akebia Therapeutics Inc1.2%
Cbs Corp New1.0%
Liberty Global Plc0.9%
0.8%
0.7%

Largest buys

Since Q3 2018, sized at quarter-end prices.

  1. Ebay Inc~$589.5MNew, 0.0% → 5.1% of the portfolio+21,000,000 shares
  2. Liberty Global Plc~$391.6MAdded, 2.3% → 5.3% of the portfolio+18,973,925 shares
  3. Univar Inc~$137.1MAdded, 0.4% → 1.5% of the portfolio+7,728,900 shares
  4. Akebia Therapeutics Inc~$135.3MNew, 0.0% → 1.2% of the portfolio+24,471,453 shares
  5. Cbs Corp New~$111.4MNew, 0.0% → 1.0% of the portfolio+2,547,059 shares
  6. Nexstar Media Group Inc~$74.7MNew, 0.0% → 0.6% of the portfolio+950,000 shares
  7. Pioneer Nat Res Co~$65.8MAdded, 5.3% → 5.1% of the portfolio+500,000 shares
  8. Shire Plc~$62.9MAdded, 0.1% → 0.7% of the portfolio+361,541 shares
  9. Antero Res Corp~$18.8MAdded, 3.6% → 2.3% of the portfolio+2,000,000 shares
  10. Sentinel Energy Svcs Inc~$16.5MNew, 0.0% → 0.1% of the portfolio+1,600,000 shares

Largest sells

Since Q3 2018, sized at quarter-end prices.

  1. Tribune Media Co~$230.4MSold out, 1.8% → 0.0% of the portfolio−5,996,042 shares
  2. Altaba Inc~$191.5MSold out, 1.5% → 0.0% of the portfolio−2,810,775 shares
  3. Cardinal Health Inc~$145.9MCut, 2.0% → 0.6% of the portfolio−3,270,833 shares
  4. Keryx Biopharmaceuticals Inc~$87.7MSold out, 0.7% → 0.0% of the portfolio−25,791,678 shares
  5. Pg&E Corp~$83.3MCut, 6.7% → 3.2% of the portfolio−3,505,307 shares
  6. Amerisourcebergen Corp~$54.8MCut, 1.9% → 1.3% of the portfolio−736,757 shares
  7. Mckesson Corp~$50.3MCut, 2.2% → 1.6% of the portfolio−455,689 shares
  8. Novagold Res Inc~$50.0MSold out, 0.4% → 0.0% of the portfolio−13,467,145 shares
  9. Gty Technology Holdings Inc~$47.6MSold out, 0.4% → 0.0% of the portfolio−4,400,000 shares
  10. Synchrony Finl~$41.7MCut, 3.9% → 3.0% of the portfolio−1,779,372 shares

Holdings

As of Dec 31, 2018; changes in shares since Sep 30, 2018.

Positions, sorted by share of the portfolio
HoldingValue
Twenty First Centy Fox IncCL A · shares −1.4% · price +3.9%21.4%$2.47B+$91.8M
Cheniere Energy IncCOM NEW · shares 0% · price −14.8%7.3%$840.3M−$146.2M
Twenty First Centy Fox IncCL B · shares −1.6% · price +4.3%7.1%$814.2M+$33.4M
Viasat IncCOM · shares 0% · price −7.8%7.0%$809.5M−$68.7M
QorvoCOM · shares −2.9% · price −21.0%5.6%$648.7M−$172.6M
Allergan PlcSHS · shares −3.9% · price −29.8%5.5%$635.6M−$270.2M
Liberty Global PlcSHS CL C · shares +176% · price −26.7%5.3%$613.9M−$81.0M
Pioneer Nat Res CoCOM · shares +13% · price −24.5%5.1%$591.8M−$170.7M
Ebay IncCOM · shares New5.1%$589.5M—
Pg&E CorpCOM · shares −18% · price −48.4%3.2%$367.5M−$344.5M
TeslaNOTE 2.375% 3/1 · shares 0% · price +18.0%3.2%$364.1M—
Synchrony FinlCOM · shares −11% · price −24.5%3.0%$341.4M−$110.9M
Antero Res CorpCOM · shares +7.5% · price −47.0%2.3%$268.4M−$221.2M
Theravance Biopharma IncCOM · shares 0% · price −21.7%2.1%$238.2M−$65.9M
Colony Cap Inc NewCL A COM · shares 0% · price −23.2%2.0%$232.5M−$70.1M
Atara Biotherapeutics IncCOM · shares 0% · price −16.0%1.9%$217.3M−$41.3M
Mckesson CorpCOM · shares −21% · price −16.7%1.6%$190.0M−$38.1M
Univar IncCOM · shares +436% · price −42.1%1.5%$168.5M−$22.9M
Amerisourcebergen CorpCOM · shares −27% · price −19.3%1.3%$149.9M−$35.9M
Akebia Therapeutics IncCOM · shares New1.2%$135.3M—
Cbs Corp NewCL B · shares New0.97%$111.4M—
Liberty Global PlcSHS CL A · shares 0% · price −26.2%0.92%$105.8M−$37.6M
Veritiv CorpCOM · shares 0% · price −31.4%0.77%$89.0M−$40.7M
Ypf Sociedad AnonimaSPON ADR CL D · shares 0% · price −13.3%0.70%$80.3M−$12.4M
Shire PlcSPONSORED ADR · shares +365% · price −4.0%0.70%$80.1M−$714,815
Total 37 positions100%$11.52B−$1.89B

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2018 to Q4 2018: 29 stocks held throughout, down $1.89B (−16.5%).

  1. Twenty First Centy Fox Inc+$91.8M+4%
  2. Twenty First Centy Fox Inc+$33.4M+4%
  3. Nexeo Solutions Inc3:1 split+$491,000+17%
  4. Pioneer Nat Res Co−$170.7M−24%
  5. Qorvo−$172.6M−21%
  6. Antero Res Corp−$221.2M−47%
  7. Allergan Plc−$270.2M−30%
  8. Pg&E Corp−$344.5M−48%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.

Reported value by quarter

Pick a quarter to see what the fund held then.

$20.00B$10.00B$0
Q1 2016Q3 2026
Every quarter's filing
Each quarter's 13F filing, newest first
QuarterReported valueFiling
Q3 2026$5.05B−7%SEC ↗
Q2 2026$5.42B+6%SEC ↗
Q1 2026$5.12B−3%SEC ↗
Q4 2025$5.28B+10%SEC ↗
Q3 2025$4.79B+16%SEC ↗
Q2 2025$4.13B+18%SEC ↗
Q1 2025$3.50B+2%SEC ↗
Q4 2024$3.43B−2%SEC ↗
Q3 2024$3.52B−3%SEC ↗
Q2 2024$3.63B−0%SEC ↗
Q1 2024$3.65B−20%SEC ↗
Q4 2023$4.59B−12%SEC ↗
Q3 2023$5.21B−7%SEC ↗
Q2 2023$5.61B−4%SEC ↗
Q1 2023$5.85B−5%SEC ↗
Q4 2022$6.13B+6%SEC ↗
Q3 2022$5.79B−14%SEC ↗
Q2 2022$6.77B−27%SEC ↗
Q1 2022$9.30B−8%SEC ↗
Q4 2021$10.13B−7%SEC ↗
Q3 2021$10.88B−12%SEC ↗
Q2 2021$12.33B−2%SEC ↗
Q1 2021$12.56B+16%SEC ↗
Q4 2020$10.84B+17%SEC ↗
Q3 2020$9.25B+15%SEC ↗
Q2 2020$8.01B+18%SEC ↗
Q1 2020$6.77B−25%SEC ↗
Q4 2019$9.06B+3%SEC ↗
Q3 2019$8.83B−20%SEC ↗
Q2 2019$11.05B−7%SEC ↗
Q1 2019$11.90B+3%SEC ↗
Q4 2018$11.52B−12%SEC ↗
Q3 2018$13.06B+14%SEC ↗
Q2 2018$11.44B+10%SEC ↗
Q1 2018$10.37B+3%SEC ↗
Q4 2017$10.11B+26%SEC ↗
Q3 2017$8.02B−8%SEC ↗
Q2 2017$8.75B+3%SEC ↗
Q1 2017$8.49B+11%SEC ↗
Q4 2016$7.67B+9%SEC ↗
Q3 2016$7.04B−4%SEC ↗
Q2 2016$7.37B+6%SEC ↗
Q1 2016$6.92BSEC ↗

Subscribe to TheInference for free